The professor of neurology at Cleveland Clinic and president of ACTRIMS noted his excitement for this year’s Forum, which will feature presentations on a variety of topics in the field of multiple sclerosis. [WATCH TIME: 2 minutes]
WATCH TIME: 2 minutes
“One of the things we strive to do in the ACTRIMS Forum, even though we have a single track—meaning that everybody's in the same room at the same time, rather than a number of things going on simultaneously—is to design a program that has something for everybody, ranging from basic laboratory science to clinical science, to clinical material, and then imaging and other modalities.”
Ahead of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2022 in West Palm Beach, Florida, NeurologyLive® sat down with Jeffrey Cohen, MD, director, Mellen Center for MS Treatment and Research, and professor of neurology, Cleveland Clinic, and president, ACTRIMS, to get a better understanding of what attendees can expect, as well as presentations he is most looking forward to. Cohen spoke on his excitement to see data presented by young investigators, as a priority of ACTRIMS is to assist in the development of these emerging scientists.
Speaking to the Kenneth P. Johnson Memorial Lecture, which will be given by Ruth Ann Marrie, MD, PhD, entitled “Comorbidity in Multiple Sclerosis: What, So What, What Now?”, Cohen stressed the importance of speaking to comorbidities as a target for therapy in MS, as presence of these conditions can delay diagnosis and further lead to an increased rate of accumulation of disability. Discussing the ACTRIMS Forum overall, Cohen said the single-track meeting will have “something for everybody,” allowing experts to interact with those of different interests and areas of expertise at this year’s in-person gathering. Organizers make a “conscious effort” to avoid the feelings of meetings where there are multiple presentations going on at once and a resultant a lack of interaction, he said.
For more coverage of ACTRIMS Forum 2022, click here.